BioSpace News Archive

ARV-378 is an orally bioavailable small molecule PROTAC designed to target and induce the degradation of the estrogen receptor protein, which plays a prominent role in the development of ER positive breast cancer.

MilliporeSigma today announced that it has signed a commercial supply agreement to manufacture viral vectors for bluebird bio for its use in potentially transformative gene therapies.

Aratana today announced the USDA Center for Veterinary Biologics granted Aratana conditional licensure for Canine Osteosarcoma Vaccine, Live Listeria Vector for the treatment of dogs diagnosed with osteosarcoma, one year of age or older.

Millendo Therapeutics announced that it has acquired Alize Pharma SAS in a stock-based transaction.

Dr. Rich Heyman has over 25 years of biopharma experience and previously served as CEO of Seragon.

He will report to Gilles Avenard, CEO of Acticor Biotech and be responsible for leading all clinical development and medical affairs at Acticor Biotech.

Dynasil Corporation of America today announced earnings attributable to common stockholders of $2.2M and $0.13 per common share for the fiscal year ended September 30, 2017 and the filing of its Annual Report on Form 10-K.

Nuritas today announced the close of a circa €16 million Series A funding round led by Chicago-based Cultivian Sandbox Ventures.

Opiant Pharma today announced that it expects that, beginning in the first quarter of 2018, it will receive 90% of royalty and milestone payments related to NARCAN sales directly from Adapt Pharma.

The team publishing the pre-clinical research includes IFM co-founder Eicke Latz, M.D., Ph.D., University of Bonn, and newly appointed IFM clinical advisory board member, Michael Heneka, M.D., Director of the Department of Neurodegenerative Diseases and Gerontopsychiatry, University Hospital of Bonn, Germany.